Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed Phase 3 Trials for Tolvaptan (DB06212)

Also known as: Autosomal Dominant Polycystic Kidney Disease / Polycystic Kidney Disease, Autosomal Dominant / ADPKD (Autosomal Dominant Polycystic Kidney Disease) / ADPKD / Polycystic Kidney, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD / Autosomal Dominant Polycystic Kidney / Kidney, Polycystic, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD) / Congenital cystic kidney disease NOS / Congenital cystic kidney disease

IndicationStatusPhase
DBCOND0050861 (Autosomal Dominant Polycystic Kidney Disease (ADPKD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01214421Open-Label Tolvaptan Study in Subjects With ADPKDTreatment
NCT01280721A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]Treatment
NCT00428948Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDTreatment
NCT02251275Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseTreatment
NCT03803124Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDBasic Science
NCT02160145Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseTreatment
NCT01022424A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]Treatment